

# Lin Shen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6605875/publications.pdf>

Version: 2024-02-01

95  
papers

12,616  
citations

117625

34  
h-index

45317

90  
g-index

97  
all docs

97  
docs citations

97  
times ranked

12652  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet</i> , The, 2010, 376, 687-697.	13.7	5,899
2	Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. <i>Science</i> , 2020, 368, .	12.6	716
3	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2021, 398, 759-771.	13.7	642
4	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	1.6	614
5	Management of gastric cancer in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e535-e547.	10.7	418
6	Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 832-842.	10.7	350
7	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	9.2	323
8	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1372-1384.	10.7	319
9	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	7.4	202
10	Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. <i>Cancer Cell</i> , 2022, 40, 277-288.e3.	16.8	177
11	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 350-358.	1.6	160
12	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). <i>Journal of Clinical Oncology</i> , 2021, 39, 704-712.	1.6	156
13	Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. <i>BMJ</i> , The, 2022, 377, e068714.	6.0	133
14	Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. <i>Journal of Clinical Oncology</i> , 2017, 35, 274-280.	1.6	124
15	Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 281-293.	2.2	117
16	Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3065-3076.	1.6	97
17	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 550-560.	10.7	96
18	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86

#	ARTICLE	IF	CITATIONS
19	Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. <i>BMC Cancer</i> , 2016, 16, 68.	2.6	82
20	Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. <i>Cancer Communications</i> , 2021, 41, 1173-1182.	9.2	77
21	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. <i>Cell Death and Disease</i> , 2018, 9, 123.	6.3	76
22	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62</i>	17.0	69
23	Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. <i>Scientific Reports</i> , 2015, 5, 8542.	3.3	66
24	Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. <i>Cancer Letters</i> , 2019, 457, 142-150.	7.2	65
25	Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. <i>Gastric Cancer</i> , 2019, 22, 1183-1192.	5.3	64
26	HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. <i>European Journal of Cancer</i> , 2018, 88, 92-100.	2.8	64
27	Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 748-756.	1.6	63
28	Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. <i>Journal of Immunotherapy</i> , 2020, 43, 139-144.	2.4	61
29	Phase I study of the recombinant humanized anti-HER2 monoclonal antibody- <sup>64</sup> Cu-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. <i>Gastric Cancer</i> , 2021, 24, 913-925.	5.3	61
30	Clinical and Prognostic Value of PET/CT Imaging with Combination of <sup>68</sup> Ga-DOTATATE and <sup>18</sup> F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.8	58
31	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	1.6	56
32	Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. <i>Cancer Science</i> , 2017, 108, 1881-1887.	3.9	51
33	CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. <i>Journal of Translational Medicine</i> , 2017, 15, 127.	4.4	45
34	Change of Body Weight and Macrophage Inhibitory Cytokine-1 during Chemotherapy in Advanced Gastric Cancer: What Is Their Clinical Significance?. <i>PLoS ONE</i> , 2014, 9, e88553.	2.5	37
35	Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 129.	8.6	37
36	Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study. <i>Cancer</i> , 2020, 126, 2086-2092.	4.1	37

#	ARTICLE	IF	CITATIONS
37	Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2018, 419, 64-74.	7.2	35
38	A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo. <i>Cell Death and Disease</i> , 2018, 9, 661.	6.3	35
39	A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. <i>Gastric Cancer</i> , 2018, 21, 782-791.	5.3	33
40	Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 20.	17.0	32
41	Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. <i>Journal of Translational Medicine</i> , 2018, 16, 15.	4.4	29
42	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	3.0	29
43	Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. <i>BMC Cancer</i> , 2015, 15, 894.	2.6	27
44	Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2015, 15, 6.	2.6	27
45	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. <i>BMC Cancer</i> , 2019, 19, 705.	2.6	27
46	YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 329-342.	2.5	27
47	Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e233-e255.	2.3	26
48	Thymidine Phosphorylase/ $\beta$ -tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. <i>BMC Cancer</i> , 2011, 11, 177.	2.6	25
49	Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. <i>Future Oncology</i> , 2012, 8, 617-624.	2.4	25
50	Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. <i>BMC Cancer</i> , 2020, 20, 131.	2.6	25
51	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e254.	4.0	23
52	A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4560-4560.	1.6	23
53	Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. <i>World Journal of Gastroenterology</i> , 2012, 18, 698.	3.3	23
54	Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. <i>Journal of Hematology and Oncology</i> , 2018, 11, 109.	17.0	22

#	ARTICLE	IF	CITATIONS
55	Ultrasensitive Gastric Cancer Circulating Tumor Cellular <i>CLDN18.2</i> RNA Detection Based on a Molecular Beacon. <i>Analytical Chemistry</i> , 2021, 93, 665-670.	6.5	22
56	HIF-2 $\alpha$ -targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma. <i>Biomaterials</i> , 2022, 284, 121512.	11.4	21
57	EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. <i>International Journal of Cancer</i> , 2019, 145, 2440-2449.	5.1	20
58	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. <i>Npj Precision Oncology</i> , 2021, 5, 36.	5.4	20
59	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 287-302.	2.2	20
60	Weight Loss Correlates with Macrophage Inhibitory Cytokine-1 Expression and Might Influence Outcome in Patients with Advanced Esophageal Squamous Cell Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6047-6052.	1.2	19
61	Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	18
62	Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. <i>Cell Death and Disease</i> , 2019, 10, 697.	6.3	18
63	Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12209.	12.2	18
64	Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization. <i>Journal of Nanobiotechnology</i> , 2022, 20, 179.	9.1	18
65	Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. <i>Clinical and Translational Medicine</i> , 2020, 10, e148.	4.0	17
66	Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. <i>Cell Death and Disease</i> , 2019, 10, 139.	6.3	16
67	Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial. <i>Medical Oncology</i> , 2014, 31, 226.	2.5	15
68	A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood. <i>Cancer Medicine</i> , 2020, 9, 6225-6233.	2.8	14
69	Voltage-dependent calcium channel $\alpha_1\text{G}$ subunit is a specific candidate marker for identifying gastric cancer stem cells. <i>Cancer Management and Research</i> , 2019, Volume 11, 4707-4718.	1.9	13
70	Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways. <i>Journal of Translational Medicine</i> , 2017, 15, 253.	4.4	11
71	Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor. <i>Future Oncology</i> , 2018, 14, 1721-1729.	2.4	11
72	Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. <i>Cancer Medicine</i> , 2019, 8, 5000-5011.	2.8	11

#	ARTICLE	IF	CITATIONS
73	The current status of and prospects in research regarding gastrointestinal stromal tumors in China. <i>Cancer</i> , 2020, 126, 2048-2053.	4.1	11
74	From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression. <i>Frontiers in Pharmacology</i> , 2021, 12, 757994.	3.5	10
75	The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma. <i>Oncologist</i> , 2014, 19, 173-174.	3.7	9
76	Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. <i>Theranostics</i> , 2019, 9, 3485-3500.	10.0	9
77	Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. <i>European Journal of Cancer</i> , 2021, 148, 1-13.	2.8	9
78	Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. <i>Oncotarget</i> , 2017, 8, 25669-25678.	1.8	9
79	Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: &#x2028;Safety, Efficacy, and Biomarkers. <i>Oncologist</i> , 2022, 27, 342-e383.	3.7	8
80	&lt;p&gt;Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 1349-1362.	1.9	7
81	Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: next generation sequencing and clinical implications. <i>Annals of Translational Medicine</i> , 2021, 9, 967-967.	1.7	7
82	Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	1.5	6
83	Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib—a multi-center cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 318-323.	1.0	6
84	Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer. <i>JAMA Network Open</i> , 2022, 5, e224637.	5.9	6
85	Glutathione-responsive PLGA nanocomplex for dual delivery of doxorubicin and curcumin to overcome tumor multidrug resistance. <i>Nanomedicine</i> , 2021, 16, 1411-1427.	3.3	5
86	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 761110.	2.8	5
87	<p>Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase Ib, Open-Label Study</p>. <i>Clinical Pharmacology: Advances and Applications</i> , 2020, Volume 12, 21-33.	1.2	3
88	Integrative analysis of genomic, epigenomic and transcriptomic data identified molecular subtypes of esophageal carcinoma. <i>Aging</i> , 2021, 13, 6999-7019.	3.1	3
89	Application of immune checkpoint inhibitors in hepatobiliary cancers. , 2022, 1, 43-48.		3
90	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2022, 172, 22-30.	2.8	3

#	ARTICLE	IF	CITATIONS
91	Paclitaxel and Cisplatin with or without Cetuximab in metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label Phase II trial. <i>Innovation(China)</i> , 2022, 3, 100239.	9.1	2
92	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4439-4450.	2.0	1
93	Reply to M. A. Liu et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 2519-2519.	1.6	0
94	CAN017, a novel anti-HER3 antibody, exerted great potency in mouse avatars of esophageal squamous cell carcinoma with NRG1 as a biomarker. <i>American Journal of Cancer Research</i> , 2021, 11, 1697-1708.	1.4	0
95	Abstract 5129: Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & anti-PD-1 agents. <i>Cancer Research</i> , 2022, 82, 5129-5129.	0.9	0